Health Care • Biotechnology: Pharmaceutical Preparations
$16.49 ▲ +0.97
(+6.25%)
MKT CAP: $2.49B • VOL: 2.45M
52W L $7 52W H $18
ROARABLE / RQD
D • 46/100
PIOTROSKI
3 / 9
BHVN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$745.4M | -$885.1M | -$436.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$738.8M | -$846.4M | -$408.2M |
| EBITDA (Normalized) | -$744.8M | -$881.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$609.4M | -$582.5M | -$331.7M |
| Capital Expenditures (CapEx) | $715.0K | $4.0M | — |
| Free Cash Flow (FCF) | -$610.2M | -$586.5M | -$331.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $230.0M | $99.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $52.1M | $423.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BHVN.